$170 million market cap with a potential bio better for a $1 billion per year market for Fabry's. Proof of platform already done via FDA approval of Elelyso. Other pipeline products being developed. If Fabry data is good this stock can go much higher quickly.
New management seems to understand the need for better products not just cheaper ones.
I am a frustrated long-term holder just not willing to give up yet.